Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Larissa University Hospital | OTHER |
| Society of Vascular and Interventional Neurology | UNKNOWN |
| Hospital de Egas Moniz | OTHER |
Not provided
Not provided
Not provided
Not provided
Case-series and cohort studies have shown the feasibility of reperfusion therapies in patients with ischemic stroke and COVID-19, but due to the absence of a contemporary control group of non-COVID-19 patients, small sample size or lack of long-term outcome assessment, concerns regarding safety and efficacy of these treatments remain to be clarified. Taking into account its limitations, some studies documented higher rates of endovascular treatment complications such as clot fragmentation with distal embolization and vessel re-oclusion, to be more difficult to achieve recanalization after endovascular treatment, and higher rates of any intracerebral hemmorhage.
The investigators aim is to assess in a large, multicenter and international cohort, the safety and outcomes of acute reperfusion therapies in patients with ischemic stroke and COVID-19, by comparison with a contemporary control group of patients with ischemic stroke and without COVID-19 from the same centers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ischemic Stroke and COVID-19 | Ischemic stroke patients with COVID-19 receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment) | ||
| Control group: Ischemic Stroke without COVID-19 | Ischemic stroke patients without COVID-19 receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Rate of symptomatic intracranial hemorrhage | Symptomatic parenchymal hemorrhagic transformation according to the ECASS-2 (European-Australasian Acute Stroke Study - II) definition, and/or subarachnoid hemorrhage with ≥4-point worsening in NIHSS (National Institute of Health Stroke Scale) | 36 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of any hemorrhagic transformation | According to the ECASS-2 (European-Australasian Acute Stroke Study - II) definition | 36 hours |
| Rate of recanalization after endovascular treatment measured by mTICI (modified treatment in cerebral infarction) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Exposed group - Patients with COVID-19
Non-exposed group - Patients without COVID-19 ("controls")
Not provided
| Name | Affiliation | Role |
|---|---|---|
| João Pedro Marto, MD | Stroke Center, Department of Neurology, Lausanne University Hospital, Lausanne, Switzerland and Deparment of Neurology, Hospital de Egas Moniz, Lisbon, Portugal | Principal Investigator |
| George Ntaios, MD, PhD | Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece | Principal Investigator |
| Davide Strambo, MD | Stroke Centre, Neurology Service, Lausanne University Hospital, Lausanne, Switzerland | Principal Investigator |
| Patrik Michel, MD | Stroke Centre, Neurology Service, Lausanne University Hospital, Lausanne, Switzerland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lausanne University Hospital | Lausanne | Switzerland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38134260 | Derived | Strambo D, Marto JP, Ntaios G, Nguyen TN, Michel P; Global COVID-19 Stroke Registry. Effect of Asymptomatic and Symptomatic COVID-19 on Acute Ischemic Stroke Revascularization Outcomes. Stroke. 2024 Jan;55(1):78-88. doi: 10.1161/STROKEAHA.123.043899. Epub 2023 Dec 22. | |
| 36351814 | Derived | Marto JP, Strambo D, Ntaios G, Nguyen TN, Herzig R, Czlonkowska A, Demeestere J, Mansour OY, Salerno A, Wegener S, Baumgartner P, Cereda CW, Bianco G, Beyeler M, Arnold M, Carrera E, Machi P, Altersberger V, Bonati L, Gensicke H, Bolognese M, Peters N, Wetzel S, Magrico M, Ramos JN, Sargento-Freitas J, Machado R, Maia C, Machado E, Nunes AP, Ferreira P, Pinho E Melo T, Dias MC, Paula A, Correia MA, Castro P, Azevedo E, Albuquerque L, Alves JN, Ferreira-Pinto J, Meira T, Pereira L, Rodrigues M, Araujo AP, Rodrigues M, Rocha M, Pereira-Fonseca A, Ribeiro L, Varela R, Malheiro S, Cappellari M, Zivelonghi C, Sajeva G, Zini A, Gentile M, Forlivesi S, Migliaccio L, Sessa M, La Gioia S, Pezzini A, Sangalli D, Zedde M, Pascarella R, Ferrarese C, Beretta S, Diamanti S, Schwarz G, Frisullo G, Marcheselli S, Seners P, Sabben C, Escalard S, Piotin M, Maier B, Charbonnier G, Vuillier F, Legris L, Cuisenier P, Vodret FR, Marnat G, Liegey JS, Sibon I, Flottmann F, Broocks G, Gloyer NO, Bohmann FO, Schaefer JH, Nolte C, Audebert HJ, Siebert E, Sykora M, Lang W, Ferrari J, Mayer-Suess L, Knoflach M, Gizewski ER, Stolp J, Stolze LJ, Coutinho JM, Nederkoorn P, van den Wijngaard I, De Meris J, Lemmens R, De Raedt S, Vandervorst F, Rutgers MP, Guilmot A, Dusart A, Bellante F, Calleja-Castano P, Ostos F, Gonzalez-Ortega G, Martin-Jimenez P, Garcia-Madrona S, Cruz-Culebras A, Vera R, Matute MC, Fuentes B, Alonso-de-Lecinana M, Rigual R, Diez-Tejedor E, Perez-Sanchez S, Montaner J, Diaz-Otero F, Perez-de-la-Ossa N, Flores-Pina B, Munoz-Narbona L, Chamorro A, Rodriguez-Vazquez A, Renu A, Ayo-Martin O, Hernandez-Fernandez F, Segura T, Tejada-Meza H, Sagarra-Mur D, Serrano-Ponz M, Hlaing T, See I, Simister R, Werring D, Kristoffersen ES, Nordanstig A, Jood K, Rentzos A, Simunek L, Krajickova D, Krajina A, Mikulik R, Cvikova M, Vinklarek J, Skoloudik D, Roubec M, Hurtikova E, Hruby R, Ostry S, Skoda O, Pernicka M, Jurak L, Eichlova Z, Jira M, Kovar M, Pansky M, Mencl P, Palouskova H, Tomek A, Jansky P, Olserova A, Sramek M, Havlicek R, Maly P, Trakal L, Fiksa J, Slovak M, Karlinski MA, Nowak M, Sienkiewicz-Jarosz H, Bochynska A, Wrona P, Homa T, Sawczynska K, Slowik A, Wlodarczyk E, Wiacek M, Tomaszewska-Lampart I, Sieczkowski B, Bartosik-Psujek H, Bilik M, Bandzarewicz A, Dorobek M, Zielinska-Turek J, Nowakowska-Kotas M, Obara K, Urbanowski P, Budrewicz S, Guzinski M, Switonska M, Rutkowska I, Sobieszak-Skura P, Labuz-Roszak BM, Debiec A, Staszewski J, Stepien A, Zwiernik J, Wasilewski G, Tiu C, Terecoasa EO, Radu RA, Negrila A, Dorobat B, Panea C, Tiu V, Petrescu S, Ozdemir A, Mahmoud M, El-Samahy H, Abdelkhalek H, Al-Hashel J, Ismail II, Salmeen A, Ghoreishi A, Sabetay SI, Gross H, Klein P, Abdalkader M, Jabbour P, El Naamani K, Tjoumakaris S, Abbas R, Mohamed GA, Chebl A, Min J, Hovingh M, Tsai JP, Khan M, Nalleballe K, Onteddu S, Masoud H, Michael M, Kaur N, Maali L, Abraham MG, Khandelwal P, Bach I, Ong M, Babici D, Khawaja AM, Hakemi M, Rajamani K, Cano-Nigenda V, Arauz A, Amaya P, Llanos N, Arango A, Vences MA, Barrientos Guerra JD, Caetano R, Martins RT, Scollo SD, Yalung PM, Nagendra S, Gaikwad A, Seo KD, Georgiopoulos G, Nogueira RG, Michel P; Global COVID-19 Stroke Registry. Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry. Neurology. 2023 Feb 14;100(7):e739-e750. doi: 10.1212/WNL.0000000000201537. Epub 2022 Nov 9. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000083242 | Ischemic Stroke |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D020521 | Stroke |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Only in EVT patients
| End of procedure |
| Rate of successful recanalization after endovascular treatment (defined as final mTICI [modified treatment in cerebral infarction] ≥2b) | Only in EVT patients | End of procedure |
| Number of passes during endovascular treatment | Only in EVT patients | End of procedure |
| Rate of first pass effect during endovascular treatment | Only in EVT patients | End of procedure |
| Rate of procedural complication (Arterial perforation, embolization into a previously non-ischemic territory, and re-occlusion) | Only in EVT patients | End of procedure |
| Delta NIHSS (National Institute of Health Stroke Scale) at 24 hours | Difference between admission NIHSS and NIHSS at 24 hours. NIHSS is a scale used to quantify the severity of neurological deficits after stroke: 0 (no signs) to 42 (very severe stroke) | 24 hours |
| 3-month modified Rankin Scale (mRS) | Functional outcome assessed with mRS at 3-month follow-up. The mRS is an ordinal scale that assigns patients among 7 levels of disability: 0 (no symptom) to 5 (severe disability) and 6 (death) | 3 months |
| 3-month favorable outcome | Favorable outcome defined as modified Rankin Scale (mRS) ≤2 or equal to pre-stroke mRS | 3 months |
| 3-month mortality | Mortality assessed at 3-month follow-up | 3 months |
| D009422 |
| Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |